Show simple item record

dc.contributor.authorNyberg, Tommy
dc.contributor.authorTischkowitz, Marc
dc.contributor.authorAntoniou, Antonis
dc.date.accessioned2021-12-14T00:31:09Z
dc.date.available2021-12-14T00:31:09Z
dc.date.issued2021-12-28
dc.identifier.issn0007-0920
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/331376
dc.description.abstractBACKGROUND: BRCA1 and BRCA2 pathogenic variants (PVs) are associated with prostate cancer (PCa) risk, but a wide range of relative risks (RRs) has been reported. METHODS: We systematically searched PubMed, Embase, MEDLINE and Cochrane Library in June 2021 for studies that estimated PCa RRs for male BRCA1/2 carriers, with no time or language restrictions. The literature search identified 27 studies (BRCA1: n = 20, BRCA2: n = 21). RESULTS: The heterogeneity between the published estimates was high (BRCA1: I2 = 30%, BRCA2: I2 = 83%); this could partly be explained by selection for age, family history or aggressive disease, and study-level differences in ethnicity composition, use of historical controls, and location of PVs within BRCA2. The pooled RRs were 2.08 (95% CI 1.38-3.12) for Ashkenazi Jewish BRCA2 carriers, 4.35 (95% CI 3.50-5.41) for non-Ashkenazi European ancestry BRCA2 carriers, and 1.18 (95% CI 0.95-1.47) for BRCA1 carriers. At ages <65 years, the RRs were 7.14 (95% CI 5.33-9.56) for non-Ashkenazi European ancestry BRCA2 and 1.78 (95% CI 1.09-2.91) for BRCA1 carriers. CONCLUSIONS: These PCa risk estimates will assist in guiding clinical management. The study-level subgroup analyses indicate that risks may be modified by age and ethnicity, and for BRCA2 carriers by PV location within the gene, which may guide future risk-estimation studies.
dc.description.sponsorshipCancer Research UK [grants C12292/A20861, C12292/A22820 and PPRPGM-Nov20\100002]; supported by the National Institute for Health Research Cambridge Biomedical Research Centre.
dc.publisherSpringer Science and Business Media LLC
dc.rightsAll Rights Reserved
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserved
dc.titleBRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis.
dc.typeArticle
dc.publisher.departmentMrc Biostatistics Unit
dc.date.updated2021-12-10T18:18:54Z
prism.publicationNameBr J Cancer
dc.identifier.doi10.17863/CAM.78827
dcterms.dateAccepted2021-12-10
rioxxterms.versionofrecord10.1038/s41416-021-01675-5
rioxxterms.versionAM
dc.contributor.orcidNyberg, Tommy [0000-0002-9436-0626]
dc.contributor.orcidTischkowitz, Marc [0000-0002-7880-0628]
dc.contributor.orcidAntoniou, Antonis [0000-0001-9223-3116]
dc.identifier.eissn1532-1827
rioxxterms.typeJournal Article/Review
pubs.funder-project-idCancer Research UK (S_3380)
pubs.funder-project-idCancer Research UK (C12292/A22820)
pubs.funder-project-idCancer Research UK (20861)
cam.issuedOnline2021-12-28
cam.orpheus.successTue Feb 01 19:02:28 GMT 2022 - Embargo updated*
cam.depositDate2021-12-10
pubs.licence-identifierapollo-deposit-licence-2-1
pubs.licence-display-nameApollo Repository Deposit Licence Agreement
rioxxterms.freetoread.startdate2022-06-28


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record